JCI table of contents: March 20, 2008(d whether other genes that are candidate...),Health

Date:3/20/2008

d whether other genes that are candidates for gene therapy approaches might pose a similar risk. A new study, carried out by Hans-Peter Kiem and colleagues, at the Fred Hutchinson Cancer Research Center, Seattle, has now indicated that early precursors of immune cells that had the gene HOXB4 delivered into them by a gammaretroviral vector became leukemic in 2 of 2 dogs and 1 of 2 macaques. In vitro analysis established a clear link between HOXB4 expression and leukemia, leading the authors to conclude that the use of HOXB4-based gene therapy would probably carry a high risk of leukemia and that extreme caution is needed when considering gene therapy approaches. The need for caution is echoed in an accompany commentary by Andre Larochelle and Cynthia E. Dunbar, at the National Institutes of Health, Bethesda, who discuss how important large animal studies, such as those reported by Hans-Peter Kiem and colleagues, are to minimize the risk of adverse events in humans receiving gene therapy in the future.

TITLE: High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector

AUTHOR CONTACT:
Hans-Peter Kiem
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Phone: (206) 667-4425; Fax: (206) 667-6124; E-mail: hkiem@fhcrc.org.

View the PDF of this article at: https://www.the-jci.org/article.php?id=34371

ACCOMPANYING COMMENTARY

TITLE: HOXB4 and retroviral vectors: adding fuel to the fire

AUTHOR CONTACT:
Cynthia E. Dunbar
National Institutes of Health, Bethesda, Maryland, USA.
Phone: (301) 496-1434; Fax: (301) 496-8396; E-mail: dunbarc@nhlbi.nih.gov.

View the PDF of this article at: https://www.the-jci.org/article.php?id=35326'/>"/>

Contact: Karen Honey press_releases@the-jci.org 215-573-1850 Journal of Clinical Investigation Source:Eurekalert

0 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Blue Cross and Blue Shield of Illinois Announces 2007 Charitable Donations
2. GSK Charitable Support Valued at $564 Million in 2007
3. JCI online early table of contents: March 13, 2008
4. Implantable medical devices may expose patients to security, privacy risks; solutions suggested
5. Perrigo Company to Market Over-the-Counter Cetirizine Hydrochloride, Pseudoephedrine Hydrochloride Extended-Release Tablets
6. Perrigo Company Announces Initial Shipments of Store Brand Omeprazole Tablets
7. V8 V-Fusion(R) Takes an Exotic, Tasty Twist on Vegetable Juice
8. JCI online early table of contents: March 3, 2008
9. AXA Equitable Meets the Needs of Two People under One Life Insurance Policy
10. Nanomedicine system engineered to enhance therapeutic effects of injectable drugs
11. Nurses Convince Hospital to Return to Bargaining Table